“Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s133, https://doi.org/10.25251/skin.7.supp.133.